Anti-inflammatory therapies for acute respiratory distress syndrome

References

• Grasselli G, Calfee CS, Camporota L, et al. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies. Intensive care Med. 2023;49(7):727–759. doi: 10.1007/s00134-023-07050-7
   PubMed Web of Science ®Google Scholar
• Villar J, Szakmany T, Grasselli G, et al. Redefining ARDS: a paradigm shift. Crit Care. 2023;27(1):416. doi: 10.1186/s13054-023-04699-w
   PubMed Web of Science ®Google Scholar
• Battaglini D, Cruz F, Robba C, et al. Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics. Expert Opin Investig Drugs. 2022;31(10):995–1015. doi: 10.1080/13543784.2022.2120801
   PubMed Web of Science ®Google Scholar
• Battaglini D, Fazzini B, Silva PL, et al. Challenges in ARDS definition, management, and identification of effective personalized therapies. J Clin Med. 2023;12(4):1381. doi: 10.3390/jcm12041381
   PubMed Web of Science ®Google Scholar
• Silva PL, Pelosi P, Rocco PRM. Personalized pharmacological therapy for ARDS: a light at the end of the tunnel. Expert Opin Investig Drugs. 2020;29(1):49–61. doi: 10.1080/13543784.2020.1699531
   PubMed Web of Science ®Google Scholar
• Rocco PR, Zin WA. Pulmonary and Extrapulmonary Acute Respiratory Distress Syndrome Are Different. Curr Opin Crit Care. 2005;11(1):10–17. doi: 10.1097/00075198-200502000-00003
   PubMed Web of Science ®Google Scholar
• Horie S, McNicholas B, Rezoagli E, et al. Emerging pharmacological therapies for ARDS: COVID-19 and beyond. Intensive care Med. 2020;46(12):2265–2283. doi: 10.1007/s00134-020-06141-z
   PubMed Web of Science ®Google Scholar
• Beitler JR, Thompson BT, Baron RM, et al. Advancing precision medicine for acute respiratory distress syndrome. Lancet Respir Med. 2022;10(1):107–120. doi: 10.1016/S2213-2600(21)00157-0
   PubMed Web of Science ®Google Scholar
• Bos LDJ, Artigas A, Constantin J-M, et al. Precision medicine in acute respiratory distress syndrome: workshop report and recommendations for future research. Eur Respir Rev. 2021;30(159):200317. doi: 10.1183/16000617.0317-2020
   PubMed Web of Science ®Google Scholar
• Ware LB, Matthay MA, Mebazaa A. Designing an ARDS trial for 2020 and beyond: focus on enrichment strategies. Intensive care Med. 2020;46(12):2153–2156. doi: 10.1007/s00134-020-06232-x
   PubMed Web of Science ®Google Scholar
• Battaglini D, Al-Husinat L, Normando AG, et al. Personalized medicine using omics approaches in acute respiratory distress syndrome to identify biological phenotypes. Respir Res. 2022;23(1):318. doi: 10.1186/s12931-022-02233-0
   PubMed Web of Science ®Google Scholar
• Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2(8):611–620. doi: 10.1016/S2213-2600(14)70097-9
   PubMed Web of Science ®Google Scholar
• Calfee CS, Delucchi KL, Sinha P, et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med. 2018;6(9):691–698. doi: 10.1016/S2213-2600(18)30177-2
   PubMed Web of Science ®Google Scholar
• Famous KR, Delucchi K, Ware LB, et al. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med. 2017;195(3):331–338. doi: 10.1164/rccm.201603-0645OC
   PubMed Web of Science ®Google Scholar
• Sinha P, Furfaro D, Cummings MJ, et al. Latent class analysis reveals COVID-19–related acute respiratory distress syndrome subgroups with differential responses to Corticosteroids. Am J Respir Crit Care Med. 2021;204(11):1274–1285. doi: 10.1164/rccm.202105-1302OC
   PubMed Web of Science ®Google Scholar
• Coppola S, Pozzi T, Gurgitano M, et al. Radiological pattern in ARDS patients: partitioned respiratory mechanics, gas exchange and Lung Recruitability. Ann Intensive Care. 2021;11(1):78. doi: 10.1186/s13613-021-00870-0
   PubMed Web of Science ®Google Scholar
• Pozzi T, Fratti I, Tomarchio E, et al. Early time-course of respiratory mechanics, mechanical power and gas exchange in ARDS patients. J Crit Care. 2024;79:154444. doi: 10.1016/j.jcrc.2023.154444
   PubMed Web of Science ®Google Scholar
• Pelosi P, Ball L, Barbas CSV, et al. Personalized mechanical ventilation in acute respiratory distress syndrome. Crit Care. 2021;25(1):250. doi: 10.1186/s13054-021-03686-3
   PubMed Web of Science ®Google Scholar
• Rizzo AN, Aggarwal NR, Thompson BT, et al. Advancing precision medicine for the diagnosis and treatment of acute respiratory distress syndrome. J Clin Med. 2023;12(4):1563. doi: 10.3390/jcm12041563
   PubMed Web of Science ®Google Scholar
• Wildi K, Livingstone S, Palmieri C, et al. The discovery of biological subphenotypes in ARDS: a novel approach to targeted medicine? J Intensive Care. 2021;9(1):14. doi: 10.1186/s40560-021-00528-w
   PubMed Web of Science ®Google Scholar
• Sinha P, Meyer NJ, Calfee CS. Biological phenotyping in sepsis and acute respiratory distress syndrome. Annu Rev Med. 2023;74(1):457–471. doi: 10.1146/annurev-med-043021-014005
   PubMedGoogle Scholar
• Marik PE, Meduri GU, Rocco PRM, et al. Glucocorticoid Treatment in Acute Lung Injury and Acute Respiratory Distress Syndrome. Crit Care Clin. 2011;27(3):589–607. doi: 10.1016/j.ccc.2011.05.007
   PubMed Web of Science ®Google Scholar
• Lin P, Zhao Y, Li X, et al. Decreased mortality in acute respiratory distress syndrome patients treated with Corticosteroids: an updated meta-analysis of randomized clinical trials with trial sequential analysis. Crit Care. 2021;25(1):122. doi: 10.1186/s13054-021-03546-0
   PubMed Web of Science ®Google Scholar
• Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids — New mechanisms for old drugs. N Engl J Med. 2005;353(16):1711–1723. doi: 10.1056/NEJMra050541
   PubMed Web of Science ®Google Scholar
• Barnes PJ. How Corticosteroids Control Inflammation: Quintiles Prize Lecture 2005: Corticosteroids and Inflammation. Br J Pharmacol. 2006;148(3):245–254. doi: 10.1038/sj.bjp.0706736
   PubMed Web of Science ®Google Scholar
• Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS. Chest. 2007;131(4):954–963. doi: 10.1378/chest.06-2100
   PubMed Web of Science ®Google Scholar
• Bernard GR, Luce JM, Sprung CL, et al. High-dose Corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med. 1987;317(25):1565–1570. doi: 10.1056/NEJM198712173172504
   PubMed Web of Science ®Google Scholar
• Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of Corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006;354(16):1671–1684. doi: 10.1056/NEJMoa051693
   PubMed Web of Science ®Google Scholar
• Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267–276. doi: 10.1016/S2213-2600(19)30417-5
   PubMed Web of Science ®Google Scholar
• Siemieniuk RAC, Meade MO, Alonso-Coello P, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med. 2015;163(7):519–528. doi: 10.7326/M15-0715
   PubMed Web of Science ®Google Scholar
• Arabi YM, Chrousos GP, Meduri GU. The Ten reasons why Corticosteroid therapy reduces mortality in severe COVID-19. Intensive care Med. 2020;46(11):2067–2070. doi: 10.1007/s00134-020-06223-y
   PubMed Web of Science ®Google Scholar
• The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704. doi: 10.1056/NEJMoa2021436
   PubMed Web of Science ®Google Scholar
• The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, et al. Association between administration of systemic Corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330. doi: 10.1001/jama.2020.17023
   PubMed Web of Science ®Google Scholar
• Lewis SR, Pritchard MW, Thomas CM, et al. Pharmacological agents for adults with acute respiratory distress syndrome. Cochrane Database Syst Rev. 2019. doi: 10.1002/14651858.CD004477.pub3
   Web of Science ®Google Scholar
• Robba C, Battaglini D, Ball L, et al. Ten Things you need to know about Intensive Care unit management of mechanically ventilated patients with COVID-19. Expert Rev Respir Med. 2021;15(10):1293–1302. doi: 10.1080/17476348.2021.1906226
   PubMed Web of Science ®Google Scholar
• Sinha P, Delucchi KL, McAuley DF, et al. Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials. Lancet Respir Med. 2020;8(3):247–257. doi: 10.1016/S2213-2600(19)30369-8
   PubMed Web of Science ®Google Scholar
• Battaglini D, Robba C, Pelosi P, et al. Treatment for acute respiratory distress syndrome in adults: a narrative review of phase 2 and 3 trials. Expert Opin Emerg Drugs. 2022;27(2):187–209. doi: 10.1080/14728214.2022.2105833
   PubMed Web of Science ®Google Scholar
• Martin-Loeches I, Nagavci B, Torres A. Final Approval for Corticosteroids in Severe CAP? For Sure, in Septic Shock. Crit Care. 2023;27(1):342. doi: 10.1186/s13054-023-04613-4
   PubMedGoogle Scholar
• Sekheri M, Rizo-Téllez SA, Othman A, et al. Interferon-β regulates proresolving lipids to promote the resolution of acute airway inflammation. Proc Natl Acad Sci. 2022;119(31):e2201146119. doi: 10.1073/pnas.2201146119
   PubMed Web of Science ®Google Scholar
• Bellingan G, Maksimow M, Howell DC, et al. The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. Lancet Respir Med. 2014;2(2):98–107. doi: 10.1016/S2213-2600(13)70259-5
   PubMed Web of Science ®Google Scholar
• Ranieri VM, Pettilä V, Karvonen MK, et al. Effect of intravenous interferon β-1a on death and days free from mechanical ventilation among patients with moderate to severe acute respiratory distress syndrome: a randomized clinical trial. JAMA. 2020;323(8):725. doi: 10.1001/jama.2019.22525
   PubMed Web of Science ®Google Scholar
• Fisher SA, Rahimzadeh M, Brierley C, et al. The role of Vitamin D in increasing circulating T regulatory cell numbers and modulating T regulatory cell phenotypes in patients with inflammatory disease or in healthy volunteers: a systematic review. PLoS One. 2019;14(9):e0222313. doi: 10.1371/journal.pone.0222313
   PubMed Web of Science ®Google Scholar
• Xu J, Yang J, Chen J, et al. Vitamin D Alleviates Lipopolysaccharide-Induced Acute Lung Injury via Regulation of the Renin-Angiotensin System. Mol Med Rep. 2017;16(5):7432–7438. doi: 10.3892/mmr.2017.7546
   PubMed Web of Science ®Google Scholar
• Shi Y-Y, Liu T-J, Fu J-H, et al. Vitamin D/VDR signaling attenuates lipopolysaccharide-induced acute lung injury by maintaining the integrity of the pulmonary epithelial barrier. Mol Med Rep. 2016;13(2):1186–1194. doi: 10.3892/mmr.2015.4685
   PubMed Web of Science ®Google Scholar
• Kong J, Zhu X, Shi Y, et al. VDR attenuates acute lung injury by blocking ang-2-tie-2 pathway and Renin-Angiotensin System. Mol Endocrinol. 2013;27(12):2116–2125. doi: 10.1210/me.2013-1146
   PubMedGoogle Scholar
• Zheng S, Yang J, Hu X, et al. Vitamin D attenuates lung injury via stimulating epithelial repair, reducing epithelial cell apoptosis and inhibits TGF-β induced epithelial to Mesenchymal transition. Biochem Pharmacol. 2020;177:113955. doi: 10.1016/j.bcp.2020.113955
   PubMed Web of Science ®Google Scholar
• Parekh D, Dancer RCA, Scott A, et al. Vitamin D to prevent lung injury following esophagectomy—A randomized, placebo-controlled trial*. Crit Care Med. 2018;46(12):e1128–e1135. doi: 10.1097/CCM.0000000000003405
   PubMed Web of Science ®Google Scholar
• The National Heart, Lung, and Blood Institute PETAL Clinical Trials Network. Early high-dose Vitamin D 3 for critically ill, Vitamin D–deficient patients. N Engl J Med. 2019;381(26):2529–2540. doi: 10.1056/NEJMoa1911124
   PubMed Web of Science ®Google Scholar
• Wei Y, Wang Z, Su L, et al. Platelet count mediates the contribution of a genetic variant in LRRC 16A to ARDS risk. Chest. 2015;147(3):607–617. doi: 10.1378/chest.14-1246
   PubMed Web of Science ®Google Scholar
• Toner P, Boyle AJ, McNamee JJ, et al. Aspirin as a treatment for ARDS. Chest. 2022;161(5):1275–1284. doi: 10.1016/j.chest.2021.11.006
   PubMed Web of Science ®Google Scholar
• Mezidi M, Guérin C. Aspirin for Prevention of acute respiratory distress syndrome (ARDS): Let’s not throw the baby with the water! Ann Transl Med. 2016;4(19):376–376. doi: 10.21037/atm.2016.07.28
   PubMed Web of Science ®Google Scholar
• Tung Y-T, Wei C-H, Yen C-C, et al. Aspirin attenuates hyperoxia-induced acute respiratory distress syndrome (ARDS) by suppressing pulmonary inflammation via the NF-κB signaling pathway. Front Pharmacol. 2022;12:793107. doi: 10.3389/fphar.2021.793107
   PubMedGoogle Scholar
• Kor DJ, Carter RE, Park PK, et al. Effect of Aspirin on development of ARDS in at-risk patients presenting to the emergency department: the LIPS-A randomized clinical trial. JAMA. 2016;315(22):2406. doi: 10.1001/jama.2016.6330
   PubMed Web of Science ®Google Scholar
• Chakraborty N, Muzaffar SN, Siddiqui SS. Aspirin cannot stop multiple pathophysiologic pathways of ARDS. Chest. 2022;161(6):e391–e392. doi: 10.1016/j.chest.2022.01.072
   PubMed Web of Science ®Google Scholar
• Azh N, Barzkar F, Motamed‐Gorji N, et al. Nonsteroidal anti‐inflammatory drugs in acute viral respiratory tract infections: an updated systematic review. Pharmacol Res Perspect. 2022;10(2). doi: 10.1002/prp2.925
   PubMed Web of Science ®Google Scholar
• Sweeney RM, McAuley DF. Do nonventilatory strategies for acute lung injury and ARDS work? In Evidence-based practice of critical care. Elsevier; 2010. p. 73–81. doi: 10.1016/B978-1-4160-5476-4.00012-2
   Google Scholar
• Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med. 1997;336(13):912–918. doi: 10.1056/NEJM199703273361303
   PubMed Web of Science ®Google Scholar
• Teafatiller T, Agrawal S, De Robles G, et al. Vitamin C enhances antiviral functions of lung epithelial cells. Biomolecules. 2021;11(8):1148. doi: 10.3390/biom11081148
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ding S, Li C, et al. Effects of N-Acetylcysteine treatment in acute respiratory distress syndrome: a meta-analysis. Exp Ther Med. 2017;14(4):2863–2868. doi: 10.3892/etm.2017.4891
   PubMed Web of Science ®Google Scholar
• Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4(12):977–987. doi: 10.1038/nrd1901
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhu Z, Jiao W, et al. Ulinastatin treatment for acute respiratory distress syndrome in China: a meta-analysis of randomized controlled trials. BMC Pulm Med. 2019;19(1):196. doi: 10.1186/s12890-019-0968-6
   PubMed Web of Science ®Google Scholar
• Feng Y. Efficacy of statin therapy in patients with acute respiratory distress syndrome/acute lung injury: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2018;22(10):3190–3198. doi: 10.26355/eurrev_201805_15080
   PubMed Web of Science ®Google Scholar
• Craig TR, Duffy MJ, Shyamsundar M, et al. A randomized clinical trial of hydroxymethylglutaryl– coenzyme a reductase inhibition for acute lung injury (the HARP study). Am J Respir Crit Care Med. 2011;183(5):620–626. doi: 10.1164/rccm.201003-0423OC
   PubMed Web of Science ®Google Scholar
• McAuley DF, Laffey JG, O’Kane CM, et al. Simvastatin in the acute respiratory distress syndrome. N Engl J Med. 2014;371(18):1695–1703. doi: 10.1056/NEJMoa1403285
   PubMed Web of Science ®Google Scholar
• Truwit JD, Bernard GR, Steingrub J, et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med. 2014;370(23):2191–2200. doi: 10.1056/NEJMoa1401520
   PubMed Web of Science ®Google Scholar
• Pienkos SM, Moore AR, Guan J, et al. Effect of total cholesterol and statin therapy on mortality in ARDS patients: a secondary analysis of the SAILS and HARP-2 trials. Crit Care. 2023;27(1):126. doi: 10.1186/s13054-023-04387-9
   PubMed Web of Science ®Google Scholar
• Xu S, Yang Q, Bai J, et al. Blockade of endothelial, but not epithelial, cell expression of PD-L1 following severe shock attenuates the development of indirect acute lung injury in mice. Am J Physiol Lung Cell Mol Physiol. 2020;318(4):L801–L812. doi: 10.1152/ajplung.00108.2019
   PubMed Web of Science ®Google Scholar
• Lomas-Neira J, Monaghan SF, Huang X, et al. Novel role for PD-1: PD-L1 as mediator of pulmonary vascular endothelial cell functions in pathogenesis of indirect ARDS in mice. Front Immunol. 2018;9:3030. doi: 10.3389/fimmu.2018.03030
   PubMed Web of Science ®Google Scholar
• Xu J, Wang J, Wang X, et al. Soluble PD-L1 improved direct ARDS by reducing monocyte-derived macrophages. Cell Death Dis. 2020;11(10):934. doi: 10.1038/s41419-020-03139-9
   PubMed Web of Science ®Google Scholar
• Pickles OJ, Lee LYW, Starkey T, et al. Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome? Br J Cancer. 2020;123(5):691–693. doi: 10.1038/s41416-020-0930-7
   PubMed Web of Science ®Google Scholar
• Christian MD, Poutanen SM, Loutfy MR, et al. Severe Acute Respiratory Syndrome. Clin Infect Dis. 2004;38(10):1420–1427. doi: 10.1086/420743
   PubMed Web of Science ®Google Scholar
• Lee JS, Shin E-C. The type I interferon response in COVID-19: implications for treatment. Nat Rev Immunol. 2020;20(10):585–586. doi: 10.1038/s41577-020-00429-3
   PubMed Web of Science ®Google Scholar
• Ishii M, Yamaguchi Y, Isumi K, et al. Transgenic mice overexpressing Vitamin D receptor (VDR) show anti-inflammatory effects in lung tissues. Inflammation. 2017;40(6):2012–2019. doi: 10.1007/s10753-017-0641-2
   PubMed Web of Science ®Google Scholar
• Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017;i6583. doi: 10.1136/bmj.i6583
   PubMed Web of Science ®Google Scholar
• Ul Afshan F, Nissar B, Chowdri NA, et al. Relevance of Vitamin D3 in COVID-19 infection. Gene Rep. 2021;24:101270. doi: 10.1016/j.genrep.2021.101270
   PubMed Web of Science ®Google Scholar
• Quesada-Gomez JM, Entrenas-Castillo M, Bouillon R. Vitamin D Receptor Stimulation to Reduce Acute Respiratory Distress Syndrome (ARDS) in Patients with Coronavirus SARS-CoV-2 Infections. J Steroid Biochem Mol Biol. 2020;202:105719. doi: 10.1016/j.jsbmb.2020.105719
   PubMed Web of Science ®Google Scholar
• Notz Q, Herrmann J, Schlesinger T, et al. Vitamin D deficiency in critically ill COVID-19 ARDS patients. Clin Nutr. 2022;41(12):3089–3095. doi: 10.1016/j.clnu.2021.03.001
   PubMed Web of Science ®Google Scholar
• De Niet S, Trémège M, Coffiner M, et al. Positive effects of Vitamin D supplementation in patients hospitalized for COVID-19: a randomized, double-blind, placebo-controlled trial. Nutrients. 2022;14(15):3048. doi: 10.3390/nu14153048
   PubMed Web of Science ®Google Scholar
• Annweiler C, Beaudenon M, Gautier J, et al. High-dose versus standard-dose Vitamin D supplementation in older adults with COVID-19 (COVIT-TRIAL): a multicenter, open-label, randomized controlled superiority trial. PLOS Med. 2022;19(5):e1003999. doi: 10.1371/journal.pmed.1003999
   PubMed Web of Science ®Google Scholar
• Cannata-Andía JB, Díaz-Sottolano A, Fernández P, et al. A single-oral bolus of 100,000 IU of Cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D—a Randomised Multicentre International clinical trial. BMC Med. 2022;20(1):83. doi: 10.1186/s12916-022-02290-8
   PubMed Web of Science ®Google Scholar
• Lefrançais E, Ortiz-Muñoz G, Caudrillier A, et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature. 2017;544(7648):105–109. doi: 10.1038/nature21706
   PubMed Web of Science ®Google Scholar
• Asaduzzaman M, Lavasani S, Rahman M, et al. Platelets support pulmonary recruitment of neutrophils in abdominal sepsis*. Crit Care Med. 2009;37(4):1389–1396. doi: 10.1097/CCM.0b013e31819ceb71
   PubMed Web of Science ®Google Scholar
• Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest. 2006;116(12):3211–3219. doi: 10.1172/JCI29499
   PubMed Web of Science ®Google Scholar
• Boyle AJ, Di Gangi S, Hamid UI, et al. Aspirin therapy in patients with acute respiratory distress syndrome (ARDS) is associated with reduced Intensive Care unit mortality: a prospective analysis. Crit Care. 2015;19(1):109. doi: 10.1186/s13054-015-0846-4
   PubMedGoogle Scholar
• Wang Y, Zhong M, Wang Z, et al. The preventive effect of antiplatelet therapy in acute respiratory distress syndrome: a meta-analysis. Crit Care. 2018;22(1):60. doi: 10.1186/s13054-018-1988-y
   PubMedGoogle Scholar
• Panka BA, De Grooth H-J, Spoelstra-de Man AME, et al. Prevention or treatment of ards with Aspirin: a review of preclinical models and meta-analysis of clinical studies. Shock. 2017;47(1):13–21. doi: 10.1097/SHK.0000000000000745
   PubMed Web of Science ®Google Scholar
• Fowler AA, Truwit JD, Hite RD, et al. Effect of Vitamin C Infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial. JAMA. 2019;322(13):1261. doi: 10.1001/jama.2019.11825
   PubMed Web of Science ®Google Scholar
• Matthay MA, Arabi YM, Siegel ER, et al. Phenotypes and personalized medicine in the acute respiratory distress syndrome. Intensive care Med. 2020;46(12):2136–2152. doi: 10.1007/s00134-020-06296-9
   PubMed Web of Science ®Google Scholar
• Zhu C, Xie J, Zhao Z, et al. PD-L1 maintains neutrophil Extracellular traps release by inhibiting neutrophil autophagy in endotoxin-induced lung injury. Front Immunol. 2022;13:949217. doi: 10.3389/fimmu.2022.949217
   PubMedGoogle Scholar
• Robba C, Battaglini D, Pelosi P, et al. Multiple Organ Dysfunction in SARS-CoV-2: MODS-CoV-2. Expert Rev Respir Med. 2020;14(9):865–868. doi: 10.1080/17476348.2020.1778470
   PubMed Web of Science ®Google Scholar
• Sabbatino F, Conti V, Franci G, et al. PD-L1 dysregulation in COVID-19 patients. Front Immunol. 2021;12:695242. doi: 10.3389/fimmu.2021.695242
   PubMedGoogle Scholar
• Dabrowska S, Andrzejewska A, Janowski M, et al. Immunomodulatory and Regenerative Effects of Mesenchymal Stem Cells and Extracellular Vesicles: Therapeutic Outlook for Inflammatory and Degenerative Diseases. Front Immunol. 2021;11:591065. doi: 10.3389/fimmu.2020.591065
   PubMed Web of Science ®Google Scholar
• Wang F, Li Y, Wang B, et al. The safety and efficacy of Mesenchymal stromal cells in ARDS: a meta-analysis of randomized controlled trials. Crit Care. 2023;27(1):31. doi: 10.1186/s13054-022-04287-4
   PubMed Web of Science ®Google Scholar
• Byrnes D, Masterson CH, Artigas A, et al. Mesenchymal Stem/Stromal cells therapy for sepsis and acute respiratory distress syndrome. Semin Respir Crit Care Med. 2021;42(1):020–039. doi: 10.1055/s-0040-1713422
   PubMedGoogle Scholar
• Lopes-Pacheco M, Robba C, Rocco PRM, et al. Current understanding of the therapeutic benefits of Mesenchymal Stem cells in acute respiratory distress syndrome. Cell Biol Toxicol. 2020;36(1):83–102. doi: 10.1007/s10565-019-09493-5
   PubMed Web of Science ®Google Scholar
• Laffey JG, Matthay MA. F ifty Y ears of R esearch in ARDS.Cell-based therapy for acute respiratory distress syndrome. Biology and potential therapeutic value. Am J Respir Crit Care Med. 2017;196(3):266–273. doi: 10.1164/rccm.201701-0107CP
   PubMed Web of Science ®Google Scholar
• Devaney J, Horie S, Masterson C, et al. Human Mesenchymal stromal cells decrease the severity of acute lung injury induced by E. Coli in the rat. Thorax. 2015;70(7):625–635. doi: 10.1136/thoraxjnl-2015-206813
   PubMed Web of Science ®Google Scholar
• Mei SHJ, Haitsma JJ, Dos Santos CC, et al. Mesenchymal Stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med. 2010;182(8):1047–1057. doi: 10.1164/rccm.201001-0010OC
   PubMed Web of Science ®Google Scholar
• Guerra AD, Cantu DA, Vecchi JT, et al. Mesenchymal Stromal/Stem cell and minocycline-loaded hydrogels inhibit the growth of staphylococcus aureus that evades immunomodulation of blood-derived leukocytes. AAPS J. 2015;17(3):620–630. doi: 10.1208/s12248-015-9728-6
   PubMed Web of Science ®Google Scholar
• Carla A, Pereira B, Boukail H, et al. Acute respiratory distress syndrome subphenotypes and therapy responsive traits among preclinical models: protocol for a systematic review and meta-analysis. Respir Res. 2020;21(1):81. doi: 10.1186/s12931-020-01337-9
   PubMed Web of Science ®Google Scholar
• Alcayaga-Miranda F, Dutra Silva J, Parada N, et al. Safety and efficacy of clinical-grade, cryopreserved menstrual blood Mesenchymal stromal cells in experimental acute respiratory distress syndrome. Front Cell Dev Biol. 2023;11:1031331. doi: 10.3389/fcell.2023.1031331
   PubMed Web of Science ®Google Scholar
• Lopes-Pacheco M, Rocco PRM. Functional enhancement strategies to potentiate the therapeutic properties of Mesenchymal stromal cells for respiratory diseases. Front Pharmacol. 2023;14:1067422. doi: 10.3389/fphar.2023.1067422
   PubMed Web of Science ®Google Scholar
• Khoury M, Cuenca J, Cruz FF, et al. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19. Eur Respir J. 2020;55(6):2000858. doi: 10.1183/13993003.00858-2020
   PubMed Web of Science ®Google Scholar
• Cruz FF, Weiss DJ, Rocco PRM. Prospects and progress in cell therapy for acute respiratory distress syndrome. Expert Opin Biol Ther. 2016;16(11):1353–1360. doi: 10.1080/14712598.2016.1218845
   PubMed Web of Science ®Google Scholar
• Zullo JA, Nadel EP, Rabadi MM, et al. The Secretome of hydrogel-coembedded endothelial progenitor cells and mesenchymal stem cells instructs macrophage polarization in endotoxemia. Stem Cells Transl Med. 2015;4(7):852–861. doi: 10.5966/sctm.2014-0111
   PubMed Web of Science ®Google Scholar
• Elman JS, Li M, Wang F, et al. A comparison of adipose and bone marrow-derived Mesenchymal Stromal cell secreted factors in the treatment of systemic inflammation. J Inflamm. 2014;11(1):1. doi: 10.1186/1476-9255-11-1
   Google Scholar
• Horie S, Gonzalez H, Brady J, et al. Fresh and cryopreserved human umbilical-cord-derived Mesenchymal stromal cells attenuate injury and enhance resolution and repair following ventilation-induced lung injury. Int J Mol Sci. 2021;22(23):12842. doi: 10.3390/ijms222312842
   PubMed Web of Science ®Google Scholar
• Emukah C, Dittmar E, Naqvi R, et al. Mesenchymal stromal cell conditioned media for lung disease: a systematic review and meta-analysis of preclinical studies. Respir Res. 2019;20(1):239. doi: 10.1186/s12931-019-1212-x
   PubMed Web of Science ®Google Scholar
• Dutra Silva J, Su Y, Calfee CS, et al. Mesenchymal Stromal Cell Extracellular Vesicles Rescue Mitochondrial Dysfunction and Improve Barrier Integrity in Clinically Relevant Models of ARDS. Eur Respir J. 2021;58(1):2002978. doi: 10.1183/13993003.02978-2020
   PubMed Web of Science ®Google Scholar
• Cruz FF, Rocco PRM. Stem-Cell Extracellular Vesicles and Lung Repair. Stem Cell Investig. 2017;4(9):78–78. doi: 10.21037/sci.2017.09.02
   PubMedGoogle Scholar
• Song Y, Dou H, Li X, et al. Exosomal miR-146a contributes to the enhanced therapeutic efficacy of interleukin-1β-primed Mesenchymal Stem cells against sepsis. Stem Cells. 2017;35(5):1208–1221. doi: 10.1002/stem.2564
   PubMed Web of Science ®Google Scholar
• Morrison TJ, Jackson MV, Cunningham EK, et al. Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by Extracellular vesicle mitochondrial transfer. Am J Respir Crit Care Med. 2017;196(10):1275–1286. doi: 10.1164/rccm.201701-0170OC
   PubMed Web of Science ®Google Scholar
• Monsel A, Zhu Y, Gennai S, et al. Therapeutic effects of human Mesenchymal Stem cell–derived microvesicles in severe pneumonia in mice. Am J Respir Crit Care Med. 2015;192(3):324–336. doi: 10.1164/rccm.201410-1765OC
   PubMed Web of Science ®Google Scholar
• Khatri M, Richardson LA, Meulia T. Mesenchymal Stem Cell-Derived Extracellular Vesicles Attenuate Influenza Virus-Induced Acute Lung Injury in a Pig Model. Stem Cell Res Ther. 2018;9(1):17. doi: 10.1186/s13287-018-0774-8
   PubMedGoogle Scholar
• Su Y, Silva JD, Doherty D, et al. Mesenchymal stromal cells-derived Extracellular Vesicles reprogramme macrophages in ARDS models through the miR-181a-5p-PTEN-pSTAT5-SOCS1 axis. Thorax. 2023;78(6):617–630. doi: 10.1136/thoraxjnl-2021-218194
   PubMed Web of Science ®Google Scholar
• Silva JD, De Castro LL, Braga CL, et al. Mesenchymal stromal cells are more effective than their Extracellular Vesicles at reducing lung injury regardless of acute respiratory distress syndrome etiology. Stem Cells Int. 2019;2019:1–15. doi: 10.1155/2019/8262849
   Web of Science ®Google Scholar
• Gorman E, Shankar-Hari M, Hopkins P, et al. Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) trial: a phase 1 trial. eClinicalmedicine. 2021;41:101167. doi: 10.1016/j.eclinm.2021.101167
   PubMedGoogle Scholar
• Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic Mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2019;7(2):154–162. doi: 10.1016/S2213-2600(18)30418-1
   PubMed Web of Science ®Google Scholar
• Wick KD, Leligdowicz A, Zhuo H, et al. Mesenchymal stromal cells reduce evidence of lung injury in patients with ARDS. JCI Insight. 2021;6(12):e148983. doi: 10.1172/jci.insight.148983
   PubMed Web of Science ®Google Scholar
• Ichikado K, Kotani T, Kondoh Y, et al. Clinical efficacy and safety of multipotent adult progenitor cells (invimestrocel) for acute respiratory distress syndrome (ARDS) caused by pneumonia: a randomized, open-label, standard therapy–controlled, phase 2 multicenter study (ONE-BRIDGE). Stem Cell Res Ther. 2023;14(1):217. doi: 10.1186/s13287-023-03451-z
   PubMed Web of Science ®Google Scholar
• O’Kane CM, Matthay MA. Understanding the role of Mesenchymal stromal cells in treating COVID-19 acute respiratory distress syndrome. Am J Respir Crit Care Med. 2023;207(3):231–233. doi: 10.1164/rccm.202209-1838ED
   PubMed Web of Science ®Google Scholar